Selective Targeting and Tissue Penetration to the Retina by a Systemically Administered Vascular Homing Peptide in Oxygen Induced Retinopathy (OIR)

被引:7
作者
Vahatupa, Maria [1 ]
Salonen, Niklas [1 ]
Uusitalo-Jarvinen, Hannele [1 ,2 ,3 ]
Jarvinen, Tero A. H. [1 ,2 ,3 ]
机构
[1] Tampere Univ, Fac Med & Hlth Technol, Tampere 33520, Finland
[2] Tampere Univ Hosp, Eye Ctr, Tampere 33520, Finland
[3] Tampere Univ Hosp, Dept Orthoped & Traumatol, Tampere 33520, Finland
基金
芬兰科学院;
关键词
vascular homing peptide; cell penetrating peptide; angiogenesis; oxygen-induced retinopathy (OIR); retina; diabetic retinopathy; retinopathy of prematurity (ROP); blood-retina barrier; targeted delivery; bystander effect; regenerative medicine; hypoxia; heparan sulphate proteoglycan; bronchopulmonary dysplasia; R-Ras; PROLIFERATIVE DIABETIC-RETINOPATHY; HYPOXIA-INDUCIBLE FACTORS; R-RAS; PANRETINAL PHOTOCOAGULATION; SMALL GTPASE; FASUDIL; ANGIOGENESIS; PERMEABILITY; EFFICACY; CANCER;
D O I
10.3390/pharmaceutics13111932
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pathological angiogenesis is the hallmark of ischemic retinal diseases among them retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Oxygen-induced retinopathy (OIR) is a pure hypoxia-driven angiogenesis model and a widely used model for ischemic retinopathies. We explored whether the vascular homing peptide CAR (CARSKNKDC) which recognizes angiogenic blood vessels can be used to target the retina in OIR. We were able to demonstrate that the systemically administered CAR vascular homing peptide homed selectively to the preretinal neovessels in OIR. As a cell and tissue-penetrating peptide, CAR also penetrated into the retina. Hyperoxia used to induce OIR in the retina also causes bronchopulmonary dysplasia in the lungs. We showed that the CAR peptide is not targeted to the lungs in normal mice but is targeted to the lungs after hyperoxia-/hypoxia-treatment of the animals. The site-specific delivery of the CAR peptide to the pathologic retinal vasculature and the penetration of the retinal tissue may offer new opportunities for treating retinopathies more selectively and with less side effects.
引用
收藏
页数:13
相关论文
共 70 条
[1]   Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments [J].
Arrigo, Alessandro ;
Bandello, Francesco .
PHARMACEUTICS, 2021, 13 (07)
[2]   Molecular pathogenesis of retinal and choroidal vascular diseases [J].
Campochiaro, Peter A. .
PROGRESS IN RETINAL AND EYE RESEARCH, 2015, 49 :67-81
[3]   N-terminal syndecan-2 domain selectively enhances 6-O heparan sulfate chains sulfation and promotes VEGFA165-dependent neovascularization [J].
Corti, Federico ;
Wang, Yingdi ;
Rhodes, John M. ;
Atri, Deepak ;
Archer-Hartmann, Stephanie ;
Zhang, Jiasheng ;
Zhuang, Zhen W. ;
Chen, Dongying ;
Wang, Tianyun ;
Wang, Zhirui ;
Azadi, Parastoo ;
Simons, Michael .
NATURE COMMUNICATIONS, 2019, 10 (1)
[4]   Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats [J].
D'Amico, Agata Grazia ;
Maugeri, Grazia ;
Bucolo, Claudio ;
Saccone, Salvatore ;
Federico, Concetta ;
Cavallaro, Sebastiano ;
D'Agata, Velia .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2017, 61 (02) :256-266
[5]   Pathological Angiogenesis Requires Syndecan-4 for Efficient VEGFA-Induced VE-Cadherin Internalization [J].
De Rossi, Giulia ;
Vahatupa, Maria ;
Cristante, Enrico ;
Arokiasamy, Samantha ;
Liyanage, Sidath E. ;
May, Ulrike ;
Pellinen, Laura ;
Uusitalo-Jarvinen, Hannele ;
Bainbridge, James W. ;
Jarvinen, Tero A. H. ;
Whiteford, James R. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2021, 41 (04) :1374-1389
[6]   A New Human Blood-Retinal Barrier Model Based on Endothelial Cells, Pericytes, and Astrocytes [J].
Fresta, Claudia G. ;
Fidilio, Annamaria ;
Caruso, Giuseppe ;
Caraci, Filippo ;
Giblin, Frank J. ;
Marco Leggio, Gian ;
Salomone, Salvatore ;
Drago, Filippo ;
Bucolo, Claudio .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (05)
[7]  
Gopal Sandeep, 2021, Open Biol, V11, P200377, DOI 10.1098/rsob.200377
[8]   Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy A Randomized Clinical Trial [J].
Gross, Jeffrey G. ;
Glassman, Adam R. ;
Liu, Danni ;
Sun, Jennifer K. ;
Antoszyk, Andrew N. ;
Baker, Carl W. ;
Bressler, Neil M. ;
Elman, Michael J. ;
Ferris, Frederick L. ;
Gardner, Thomas W. ;
Jampol, Lee M. ;
Martin, Daniel F. ;
Melia, Michele ;
Stockdale, Cynthia R. ;
Beck, Roy W. .
JAMA OPHTHALMOLOGY, 2018, 136 (10) :1138-1148
[9]   Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy A Randomized Clinical Trial [J].
Gross, Jeffrey G. ;
Glassman, Adam R. ;
Jampol, Lee M. ;
Inusah, Seidu ;
Aiello, Lloyd Paul ;
Antoszyk, Andrew N. ;
Baker, Carl W. ;
Berger, Brian B. ;
Bressler, Neil M. ;
Browning, David ;
Elman, Michael J. ;
Ferris, Frederick L., III ;
Friedman, Scott M. ;
Marcus, Dennis M. ;
Melia, Michele ;
Stockdale, Cynthia R. ;
Sun, Jennifer K. ;
Beck, Roy W. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (20) :2137-2146
[10]   Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency [J].
Gupta, Nilesh ;
Rashid, Jahidur ;
Nozik-Grayck, Eva ;
McMurtry, Ivan F. ;
Stenmark, Kurt R. ;
Ahsan, Fakhrul .
MOLECULAR PHARMACEUTICS, 2017, 14 (03) :830-841